key: cord-0289986-vhaxwwob authors: Alon, Assaf; Lyu, Jiankun; Braz, Joao M.; Tummino, Tia A.; Craik, Veronica; O’Meara, Matthew J.; Webb, Chase M.; Radchenko, Dmytro S.; Moroz, Yurii S.; Huang, Xi-Ping; Liu, Yongfeng; Roth, Bryan L.; Irwin, John J.; Basbaum, Allan I.; Shoichet, Brian K.; Kruse, Andrew C. title: Crystal structures of the σ2 receptor template large-library docking for selective chemotypes active in vivo date: 2021-04-30 journal: bioRxiv DOI: 10.1101/2021.04.29.441652 sha: 9f6582a86e515c6c6b9d0fbfda37f9f1c59b3b36 doc_id: 289986 cord_uid: vhaxwwob The σ2 receptor is a poorly understood transmembrane receptor that has attracted intense interest in many areas of biology including cancer imaging, Alzheimer’s disease, schizophrenia, and neuropathic pain. However, little is known regarding the molecular details of the receptor, and few highly selective ligands are available. Here, we report the crystal structure of the σ2 receptor in complex with the clinical drug candidate roluperidone and the probe compound PB28. These structures, in turn, templated a large-scale docking screen of 490 million make-on-demand molecules. Of these, 484 compounds were synthesized and tested, prioritizing not only high-ranking docked molecules, but also those with mediocre and poor scores. Overall, 127 compounds with binding affinities superior to 1 μM were identified, all in new chemotypes, 31 of which had affinities superior to 50 nM. Intriguingly, hit rate fell smoothly and monotonically with docking score. Seeking to develop selective and biologically active probe molecules, we optimized three of the original docking hits for potency and for selectivity, achieving affinities in the 3 to 48 nM range and to up to 250-fold selectivity vs. the σ1 receptor. Crystal structures of the newly discovered ligands bound to the σ2 receptor were subsequently determined, confirming the docked poses. To investigate the contribution of the σ2 receptor in pain processing, and to distinguish it from the contribution of the σ1 receptor, two potent σ2-selective and one potent σ1/σ2 non-selective ligand were tested for efficacy in a mouse model of neuropathic pain. All three ligands demonstrated timedependent decreases in mechanical hypersensitivity in the spared nerve injury model, supporting a role for the σ2 receptor in nociception, and a possible role for σ1/σ2 polypharmacology. This study illustrates the opportunities for rapid discovery of in vivo active and selective probes to study under-explored areas of biology using structurebased screens of diverse, ultra-large libraries following the elucidation of protein structures. The σ receptors are integral membrane proteins widely expressed in both the central nervous system and in peripheral tissues, including the liver and kidney. The σ receptors are divided into σ 1 and σ 2 "subtypes" based on differences in tissue distribution and in pharmacological profile 1 , but despite their names, the two proteins are entirely unrelated in sequence. Cloned in 1996, the σ 1 receptor has no paralog within the human genome; its closest homolog of known function is the yeast Δ 8,7 sterol isomerase ERG2 2 . Pharmacological studies conducted on σ 1 knockout mice 3 showed that the σ 2 is not a splice variant or other modified form of σ 1 , but rather derives from an unrelated gene. The molecular identity of the σ 2 receptor remained unknown until recently, when we purified it from calf liver tissue 4 and showed that it is TMEM97, an ER-resident membrane protein that regulates the sterol transporter NPC1 5, 6 . TMEM97 is predicted to be a four-helix bundle protein with both amino and carboxy termini facing the cytoplasm. A member of the EXPERA family 7 , the σ 2 receptor is distantly related to emopamil-binding protein (EBP), the mammalian Δ 8,7 sterol isomerase required for cholesterol synthesis, as well as to other proteins in this family, including TM6SF2, which regulates liver lipid homeostasis 8 . Despite relatively little being known about the role of σ 2 in baseline physiological processes, the receptor has been implicated in multiple disease states. For example, the σ 2 receptor is overexpressed in proliferating cells and in many tumors 9 , and labeled σ 2 ligands have been proposed as tools for diagnosis and therapy for various cancers 10, 11 . Additionally, the σ 2 receptor was recently identified as an interaction partner of the SARS-CoV-2 viral protein, Orf9c, during cellular infection 12 . Recently it was reported that a ternary complex between the σ 2 receptor, PGRMC1, and the LDL receptor increases the rate of LDL internalization 13 . Consistent with its high expression in the nervous system, the σ 2 receptor has also been proposed as a target for the treatment of multiple nervous system disorders. The σ 2 receptor ligand Elayta (CT1812) is currently in clinical trials for mild to moderate Alzheimer's disease 14 , and another ligand, roluperidone, (MIN-101) is in clinical development for treatment of the negative symptoms of schizophrenia [15] [16] [17] . When tested in animal models, σ 2 receptor ligands reduce alcohol-withdrawal symptoms 18, 19 and have a neuroprotective effect in brain injury 20 . Finally, recent studies have implicated σ 2 in chronic pain 19, 21, 22 , with σ 2 ligands having anti-allodynic effects in nerve-injury induced models of neuropathic pain. As this is also thought to be true of σ 1 ligands, and because most σ 2 ligands cross-react with the σ 1 receptor, probe ligands selective for σ 2 over σ 1 would help illuminate σ 2 biology and could be leads for novel therapeutics. However, given the relatively recent determination of the σ 2 receptor's molecular identity relatively little is known regarding its molecular architecture, ligand recognition, or amenability to methods like virtual screening for ligand identification [23] [24] [25] [26] [27] [28] [29] [30] . Here, we employed a biochemical and structural approach combined with computational docking to address these issues. The human σ 2 receptor was expressed in Sf9 insect cells and was extracted with lauryl maltose neopentyl glycol (LMNG) detergent and purified as described 4 . Size exclusion chromatography multi-angle light scattering (SEC-MALS) experiments showed that the receptor is a dimer in solution, and that the presence of ligands did not perturb this oligomeric state ( Supplementary Information Fig. 1a) . As the human σ 2 receptor did not lend itself to structural studies, further experiments were performed with the bovine σ 2 receptor, which was more tractable. Circular dichroism (CD) experiments showed that the bovine σ 2 receptor has a 74% helical content ( Supplementary Information Fig. 1b) , in agreement with secondary structure predictions. CD thermal unfolding experiments demonstrated that the receptor is remarkably stable compared to most mammalian membrane proteins, with a midpoint of the unfolding transition (T m ) of 54 °C (Supplementary Information Fig. 1c) . The T m increased by 1-3 °C when the receptor was incubated with various ligands. Several rounds of construct optimization and of crystallization conditions led to high-quality diffracting crystals of the bovine σ 2 receptor by the lipidic cubic phase method ( Supplementary Information Fig. 2a-c) . Three data sets were collected, one with receptor bound to the high-affinity non-selective ligand PB28 31 , to a resolution of 2.94 Å, another with receptor bound to the schizophrenia drug candidate roluperidone at a resolution of 2.7 Å, and yet another with the receptor bound to a ligand tentatively modeled as cholesterol at a resolution of 2.6 Å. The σ 2 receptor has no homologs with known structure, and a BLAST search against the Protein Data Bank yielded no results. A more sensitive hidden Markov model search with HHpred 32 identified EBP as a distant homolog, consistent with both proteins being members of the EXPERA family 7 . We used the structure of EBP 33 to build a homology model of the σ 2 receptor and performed a molecular replacement search that generated a marginally interpretable electron density map. Manual placement of an additional copy of the σ 2 receptor followed by iterative manual building and reciprocal space refinement led to high-quality final structure ( Supplementary Information Table 1 ). Overall structure of the σ 2 receptor The three initial σ 2 receptor crystal structures are highly similar, with a backbone root mean square deviation (RMSD) of 0.71 Å. As anticipated from multi-angle light scattering, the structures showed that σ 2 is an intimately associated homodimer, burying 890 Å 2 of surface area in dimer interface that is mainly formed by transmembrane helix 3 (TM3; Fig. 1a ). The two protomers adopt the same conformation (backbone RMSD of 0.34 Å), with each protomer showing the expected four-helix bundle fold with both the amino and carboxy termini facing the same face of the membrane, likely the cytosolic face. The four transmembrane helices of the protein are all kinked due to the presence of proline residues in each helix, creating a cavity slightly above the center of the membrane, nearer the ER-facing side of the membrane. Surprisingly, the ligand-binding cavity is entirely occluded from solvent by extracellular loops 1 and 2, which form a wellordered cap over the luminal surface of the protein. Asp56, which was shown to be crucial for ligand binding 4 , is located in extracellular loop 1 and is involved in a network of hydrogen bonds likely important for proper folding ( Supplementary Information Fig. 2d ), hence the deleterious effect of mutating this residue on binding 4 . Instead of opening to the lumen of the ER, the pocket opens laterally into the lipid bilayer (Fig. 1b) , reminiscent of lipid-binding G protein-coupled receptors 34 . The opening to the binding pocket is lined with hydrophobic and aromatic residues. Ligands may enter through this opening in their neutral, deprotonated form, and then become protonated in the binding site, allowing formation of a salt bridge with the conserved Asp29 ( Fig. 1c-d) . A second highly conserved acidic residue, Asp73, is located 3 Å away from Asp29, suggesting that these residues are hydrogen-bonded to each another, implying that Asp73 is likely protonated. The two σ receptors are not homologs and do not share the same fold; the σ 2 receptor is a four-helix bundle, while the σ 1 receptor has a β -barrel cupin fold 35 . Despite this, the binding pockets of the two receptors are remarkably similar (Fig. 1c-e) , placing functionally similar amino acids in cognate spatial positions, which is perhaps the result of convergent evolution and explains how two very different folds can share the same pharmacology. It is noteworthy that both σ receptors are homologs of proteins that catalyze the same step in sterol biosynthesis. The σ 1 receptor is a homolog of ERG2, the yeast Δ 8,7 sterol isomerase; the σ 2 receptor is a homolog of EBP, the mammalian enzyme that performs the same catalytic step in the biosynthesis of cholesterol. Both EBP and ERG2 rely on two similarly placed acidic residues in their active site for catalysis, which is thought to occur by protonation of the substrate at carbon 9 (C9) followed by proton abstraction from C7, which shifts the double bond into the C8-C7 position. All necessary components for catalysis appear to be present in σ 2 receptor, in addition to the conserved polar residues His21, Gln77, and Thr110, located at the distal end of the ligand cavity, which may aid in recognizing the hydroxyl moiety of sterols. However, the σ 2 receptor cannot act as a sterol isomerase. It can neither function in vivo to rescue a strain of yeast that lacks ERG2 ( Supplementary Information Fig. 3a ) nor can it function in vitro to convert zymostenol to lathosterol ( Supplementary Information Fig. 3b ). The same is true for the σ 1 receptor, which also has all the residues expected to be required for catalysis and also cannot rescue yeast that lack a sterol isomerase. It was recently reported that Δ 8-9 sterols serve as signaling molecules 36 , which may hint at a possible physiological function of the σ receptors as sensors of these molecules evolved from enzymes that would modify them. Docking 490 million molecules against the σ 2 receptor A prospective docking screen against the σ 2 receptor had two goals. The first was to discover novel chemotypes with potential σ 2 selectivity. The second goal was to investigate whether docking scores predict binding likelihood 38 . This second goal we undertook quantitatively, with a 3-fold larger library than previously used 38 . Moreover, the σ 2 site, with its high propensity to bind ligands, promised a higher dynamic range than the first study against the dopamine receptor. We modeled a hit rate curve as a function docking score against the σ 2 receptor. Guided by score supplemented by manual selection among the highest-ranking docked molecules, we chose 484 makeon-demand molecules spread among 14 scoring bins covering the highest-ranking (-65 to -57.5 kcal/mol), mid-ranking (-55 to -40 kcal/mol), and low-ranking docking scores (-37.5 to -22.5 kcal/mol). We note that these ranges are true for σ 2 , but they will vary among other targets. Typically, around 40 molecules per scoring bin were selected. Overall, 412 molecules were picked automatically, whereas 72 were picked by manual visual inspection. We tested compounds at 1 μ M concentration and defined as "hits" those that displaced greater than 50% [ 3 H]-DTG σ 2 binding. Based on this threshold, 127 of 484 molecules qualified as hits, equal to an overall hit rate of 26% of compounds tested, and a hit rate of over 60% at the peak among the top-ranked molecules (Fig. 2a) . Plotting docking score vs hit-rate resulted in a curve where, with one key exception (see below), hit-rates fell monotonically with score, with a slope of -4.2%/(kcal/mol) in the inflection region. The curve dropped from a hit rate of 61% at a docking score of about -60 kcal/mol, to 0% at -40 kcal/mol, where it essentially remained for the next 4 (worse) scoring bins (Fig. 2b) . Intriguingly, the hit rate among the very top scoring compounds, 27%, was meaningfully lower than those of the following four bins, and much lower than the 61% hit-rate observed in the 2 nd -best scoring bin. This dip in the hit-rate curve illuminates holes in the scoring function that can be optimized in future studies. Examination of the 41 molecules (out of 490 million docked) that rank in this very top bin showed that many of these cationic molecules have unexpectedly low desolvation penalties versus electrostatic interaction energy ( Supplementary Information Fig. 4a and 4b , the left column). Conversely, their van der Waals energies are undistinguishable among the first three bins ( Supplementary Information Fig. 4c , the left column). These results implied that the desolvation penalties were underestimated for the molecules in the very top bin, especially for an electrostatics-driven site like the σ 2 receptor site with a charged anchor residue (Asp29). A possible explanation for this drop in hit rate among the top-ranked molecules was an underestimation of ligand desolvation penalties. DOCK3.7 pre-calculates these energies based on one conformation from among hundreds of that are docked, and not necessarily the conformation that is the highest scoring against a target. Whereas different conformations of the same molecule typically have similar desolvation energies, they can differ, especially for charged molecules. Thus, a molecule can adopt a conformation that optimally complements a receptor electrostatically while only paying the desolvation cost of another, less costly conformation. Accordingly, we recalculated ligand desolvation energy using the docked conformation for all the molecules experimentally tested against σ 2 and D4 receptors. After recalculation, the molecules in the first, top-scoring bin received much higher desolvation penalties than the following bins ( Supplementary Information Fig. 4d ). This supports the idea that the artifactually favorable scores of the very top-ranked molecules come at least partly from inappropriate desolvation penalties; this, and other holes in the scoring function, merit further investigation and optimization. Naturally, in addition to testing docking-based prioritization, we were interested in finding new, potent, and selective σ 2 receptor ligands. To supplement molecules prioritized by score alone, we also picked high-ranking molecules by human inspection 39 . As a comparable number of high-ranking molecules (the first 3 scoring bins) were picked manually and by docking score alone, we could investigate what human inspection added, if anything. In these top three scoring bins, covering 139 molecules (all high scoring), the hit rate by human inspection (67%) was higher than the hit rate by docking score alone (33%) (Supplementary Information Fig. 5a and 5b) . Human-picked molecules were biased toward higher affinities, at least for those picked from the highest ranks by score: four had K i values < 5 nM and twelve had K i values < 50 nM. For those machine-picked only by score, two had K i values < 5 nM and seven had K i values < 50 nM ( Supplementary Information Fig. 5c ). While it seems clear that the human-picked molecules were more likely to be active, whether their potencies were significantly different from those picked by score alone was less clear. It's important to emphasize that all of these molecules, human-and machine-prioritized, had highly favorable scores that put them at the very top of the rank-ordered list. To find potent leads to selective probes for the σ 2 receptor, we measured concentration-response curves for the primary screen-derived 14 docking hits with the best radioligand displacement at 1 μ M. K i values ranged from 2.4 to 68 nM. To measure selectivity, we ran competition binding assays against the σ 1 receptor, observing K i values from 1.6 nM to 1.5 µM (Fig. 2d (Fig. 3a, Fig. 3b and Supplementary Information Table 1 ). Newly predicted hydrogen-bond interactions with Gln77 and the backbone carbonyl of Val146, which were not seen in the roluperidone or PB28 complexes, corresponded well between docked and crystallographic poses. The higher resolution of this structure, 2.4 Å, revealed an ordered water molecule in one of the binding site sub-pockets, coordinated by residues His21, Tyr103, and Gln77, and by an azaindole nitrogen in Z1241145220 (Fig. 3b) . To investigate whether this ordered water is important for ligand recognition, we tested two analogues that were designed to disrupt the hydrogen bonds between Gln77 and the water (Fig. 3c) . Z295861754, which is only expected to hydrogen-bond with the water but not with Gln77, showed an ~8-fold decrease in binding affinity whereas Z163048780, which is not expected to hydrogen bond with either Gln77 or the water, had a K i value > 10 µM (Fig. 3d) , indicating a crucial role of the water in the binding of Z1241145220 to the σ 2 receptor. To generalize these findings further, and to test whether this water is a structural element of the binding site, we generated a series of σ 2 mutants in which the coordination of this water molecule was disrupted. We measured the affinity of the radioligand probe [ 3 H]-DTG to these mutants and then performed competition binding assays with Z1241145220 ( Supplementary Information Fig. 7) . These experiments showed that mutating either His21 or Gln77 reduces the affinity of Z1241145220 by an order of magnitude. Taken together, these results demonstrate that the ordered water is an integral part of the binding pocket and is required for high-affinity binding of Z1241145220, and potentially for other ligands as well. This is reminiscent of a structural water molecule required for ligand recognition at the µ-opioid receptor 40 . There is strong genetic 41, 42 and pharmacological [43] [44] [45] evidence supporting a contribution of σ 1 to chronic pain 46 , but only recently, with the discovery of the gene encoding for σ 2 4 , has it been fully possible to understand and distinguish the roles of σ 2 and σ 1 in these processes 21, 22 . However, the limited availability of highly selective σ 2 probes 22 has hindered disentangling the contribution of σ 1 and σ 2 in these processes. To investigate this, we treated mice with three high-affinity σ 2 ligands with differing degrees of selectivity: Z4857158944 (4 nM; >250-fold σ 2 /σ 1 selectivity), Z1665845742 (5 nM; 47-fold σ 2 /σ 1 selectivity), and Z4446724338, a 3 nM non-selective ligand (Fig. 4a) . As a comparator, we also treated with the well-known reagent PB28, a 5 nM σ 1 /σ 2 non-selective ligand 31 . In pharmacokinetics experiments, the three docking-derived ligands had substantial brain permeability, with brain to plasma ratios ranging from 3 to 16, and brain half-lives ranging from 1.2 to 12 hours (Supplementary Information Table 4 ). The non-selective PB28 also had high brain permeability and a relatively long half-life, though its brain C max was three to eight-fold lower than that of the new dockingderived compounds. Even so, the high brain exposures of all four compounds encouraged us to examine them in a neuropathic pain model in mice. We tested the efficacy of these σ 1 and σ 2 ligands in the spared nerve injury (SNI) mouse model of neuropathic pain, in which two out of three branches of the sciatic nerve are transected 47 , resulting in significant mechanical hypersensitivity (allodynia) transmitted by the uninjured peripheral (sural) nerve. SNI mice systemically injected with either of the σ 2 -selective ligands Z1665845742 or Z4857158944 were strongly antiallodynic when dosed in SNI mice, significantly increasing mechanical thresholds versus vehicle (Fig. 4b, Supplementary Information Fig. 8a) . Intriguingly, anti-allodynic effect of Z1665845742 and Z4857158944 was comparable to that attained by a systemic injection of the σ 1 -selective ligand PD-144418. To investigate the possible synergistic effect of targeting both σ receptors we tested the nonselective ligands PB28 and Z4446724338. Systemic injection Z4446724338 dose-dependently increased the mechanical thresholds of SNI mice, 1-hour post-injection (Fig 4b, Supplementary Information Fig. 8a) , with the highest dose completely reversing the SNI-induced mechanical allodynia (i.e., thresholds returned to pre-injury levels). In contrast, systemic injections of PB28, a well-established sigma receptor ligand with high affinity for both subtypes 48 , produced mixed results, with anti-allodynic effects observed only in 60% of the mice ( Supplementary Information Fig. 8a) . The much stronger anti-allodynia of Z4446724338 versus PB28 may reflect the former's substantially higher brain permeability as measured by their respective brain C max values ( Supplementary Information Table 4) . Importantly, none of the new σ 1 and σ 2 ligands were sedative on the rotarod test ( Supplementary Information Fig. 8b) , indicating that their antiallodynic effect was not due to motor impairment. On its face, substantial anti-allodynic effects of the σ 2 -selective ligands Z1665845742 and Z4857158944 suggest that this receptor is a potential target for managing neuropathic pain in the clinic. However, because σ 2 ligands are notorious for activity at other targets, especially GPCRs 49,50 , we counter-screened all three dockingderived ligands against a panel of potential off-targets. In a TANGO screen 51 of 320 GPCRs, the molecules did not act as agonists or inverse agonists against most targets. Some activity was observed at the 5HT1A receptor and κ -opioid receptors ( Supplementary Information Fig. 9 ), but this activity did not replicate in subsequent concentration-response assays. Because a key pain target, the µ-opioid receptor, is often relatively inactive in TANGO assays, we further tested the molecules in G protein assays against this receptor; here too, no substantial activity was observed ( Supplementary Information Fig. 9 ). Since the TANGO assay is limited to detecting agonism (and in some cases inverse-agonism) at GPCRs, we further screened the compounds in binding assays against a panel of 44 targets including GPCRs, ion channels, and transporters. No binding was observed for any pain-related targets (Supplemental Information Table 5 ). Taken together, these observations suggest that the primary mechanism of action of the selective ligands is via the σ 2 receptor (naturally, other targets, not tested here, cannot be excluded). The even stronger activity of the σ 1/2 ligand Z4446724338 suggests that σ 1/2 polypharmacology may further increase activity. In earlier studies, σ 1/2 ligands showed peak antiallodynic effects up to 48 hours after dosing 21 . This unusual behavior was observed with ligands with mid-nanomolar potency for the σ 2 receptor, and 9 to 14-fold selectivity vs. the σ 1 receptor. We thought it interesting to further explore this with the low nanomolar affinity selective ligands, Z4857158944 and Z1665845742, and the joint σ 1/2 ligand, Z4446724338. The three molecules were tested post SNI, at 1 hour, 24 hours, and 48 hours after dosing. Consistent with earlier reports, the anti-allodynic effects of the three novel σ ligands increased over time, reaching maximal effect 24 hours post-injection (Fig. 4c) . In contrast, the anti-allodynic effect of the selective (Fig. 4d) . We additionally found that the expression level of Supplementary Information Fig. 8a. c The σ 2 receptor has been pharmacologically enigmatic for 30 years. Its implication in diverse biological processes and lack of molecular data has hindered progress in understanding its biological role. Four key observations from this study begin to illuminate these issues. First, high-resolution crystal structures of the σ 2 receptor complexed with roluperidone and with PB28 reveal a ligand-binding site deeply embedded in the membrane (Fig. 1a-b) , suggesting the possibility of a lipid as an endogenous ligand. The evolutionary connection of σ 2 to EBP and the structure of the receptor bound to cholesterol strongly imply an ability to recognize sterols. The structures explain the simple pharmacophore of σ 2 ligands-a positively charged amine that ion-pairs with Asp29, while flanking hydrophobic and aromatic moieties are recognized by nearby aromatic residues, such as Phe66, Phe69, His21 and Tyr50. The structures also highlight nearby polar residues, such as Gln77, and Thr110, that seem rarely exploited by classic σ 2 ligands, but which may provide new selectivity determinants for ligand discovery (Fig. 1c and 1d) . Second, by testing 484 compounds across docking ranks from a library of 490 million molecules, a clear and quantitative relationship emerged between docking score and the likelihood of binding (Fig. 2) . Encouragingly, crystal structures of docking-derived ligands confirmed the docking predictions with low RMSDs (Fig. 3a and 3b) . Third, from among the top-ranking docking hits were 31 novel scaffolds with potent binding affinities (K i < 100 nM) ( Supplementary Information Table 2-3) . Optimization of two of these led to ligands with low nanomolar affinities and 47-fold to >250-fold selectivity for the σ 2 over the σ 1 receptor ( Supplementary Information Fig. 1) . Fourth, three new σ 2 chemotypes, one non-selective but potent vs. σ 1 /σ 2 , and two others selective for σ 2 over σ 1 , were tested for efficacy in a mouse model for neuropathic pain. All three showed antiallodynic effects (Fig. 4) ; the expression pattern of the receptor and the activity of the 22, 52 for the σ 2 receptor, which has hindered understanding its role in biology and in disease. We sought to optimize for selective ligands from among our potent docking actives. We adopted a chemical novelty approach described previously 29, 53, 54 prioritizing novel scaffolds, modeled to interact with diverse groups within the σ 2 structure. We reasoned that this would identify more potent molecules that would also be selective vs the σ 1 receptor. This strategy has been productive previously, while the more rational approach of intentionally counter-docking vs. the off-target, here the σ 1 receptor, remains a research area 55 . A cycle of structure-based analoging resulted in improved selectivity for two chemotypes. Increasing the linker length in ZINC450573233 by one carbon, along with two other small changes, results in Z1665845742, with selectivity improved from 30-fold to 47fold. At the same time, replacing the 2,3-dihydro-1,4-benzodioxine group in ZINC895657866 with a 3,4-dihydro-1H-quinolin-2-one to engage with Gln77 (Fig. 3a) , led to Z4857158944, with selectivity increased from 46-fold to >250-fold, making it among the most potent and selective σ 2 ligands of which we are aware. We combined one of these selective molecules with a close analog that is inactive on the σ 2 receptor, affording a "probe pair" (Z1665845742 and Z1665798906) ( Supplementary Information Fig. 10) . Such probe pairs are useful to understand the role of receptors, such as the σ 2 in cellular and in vivo studies, where the activity of the inactive member controls for off-targets that any molecule inevitably has. The approach should also facilitate disentangling the role of the σ 2 receptor in indications for which it has been widely mooted, including cancer 9-11 , schizophrenia 17 , and Niemann Pick disease 5,6 . We make this probe pair openly available via Sigma-Millipore's probe collection (Cat. No. Certain caveats bear airing. While our ultimate goal was to find σ 2 -selective ligands from the docking, ligands with a spectrum of affinities and selectivities for both σ receptors emerged, reflecting the similarities of their pockets and the historical precedence in their overlapping pharmacology (Fig. 4c-e) . Human inspection of molecules revealed an unusually high 66% hit rate, as well as competitive ligand potency, likely reflecting a site that is well-suited to ligand binding, despite its solventocclusion and hydrophobicity. These high hit rates, potencies, and selectivities often do not translate to other targets-this target was unusually propitious for library docking. Additionally, while the docking-predicted pose for Z4857158944 and for Z1241145220 closely resembled the subsequent crystallographic structure, important differences remain, namely the water-bridging interaction for Z1241145220. Although modeling this water was not necessary for ligand discovery, and the docked ligands fit well without it, including this water modeling may further improve future structure-based efforts against this target. Modeling waters in docking remains a research area in molecular docking 56 . The key observations of this work should not be obscured by these caveats. The high-resolution crystal structures of σ 2 receptors reveal the origins of its molecular recognition, and template structure-based campaigns for novel ligand discovery. This work emphasizes the value of a structure-based approach to screen vast new libraries of chemotypes unrelated to known ligands with unique properties that illuminate the biology of the σ 2 receptor. Applications to other targets should undoubtedly be considered. Protein expression and purification for crystallography. The bovine σ 2 receptor was cloned into pVL1392 with an N-terminal human protein C epitope tag followed by a 3C protease cleavage site. The construct was truncated after residue 168 to exclude the ER localization signal for better expression and to facilitate crystallization. This receptor construct was expressed in Sf9 insect cells (Expression Systems) using the BestBac baculovirus system (Expression Systems) according to manufacturer's instruction. Infection was performed when cell density reached 4x10 6 Data reduction and refinement. Diffraction data were processed in HKL2000 58 and in XDS 59 , and statistics are summarized in Supplementary Information Table 1 . The PB28-bound structure was solved using molecular replacement starting with a Rosetta homology model generated using the structure of EBP (Protein Data Bank accession 6OHT). Matthews probability predicted four copies in the asymmetric unit. Initially, a single copy of this model was placed using Phaser. This model did not fit well into density and was replaced with Idealized helices that were used as a search model for a search for an additional copy. The resulting dimer was duplicated and manually placed into unmodeled density. The resulting structure was iteratively refined in Phenix 60 The resulting docking setup was evaluated for its ability to enrich known σ 2 ligands over property-matched decoys. Decoys are unlikely to bind to the receptor because despite their similar physical properties to known ligands, they are topologically dissimilar. We extracted 10 known σ 2 ligands from ChEMBL(https://www.ebi.ac.uk/chembl/) including PB28 and roluperidone whose crystallographic poses were report here. Five-hundred and forty-two property-matched decoys were generated by the DUDE-Z pipeline 67 . Docking performance was evaluated based on the ability to enrich the knowns over the decoys by docking rank, using log adjusted AUC values (logAUC). The docking setup described above is able to achieve a high logAUC of 39 and to recover the crystal poses of PB28 and roluperidone with RMSD values of 0.93 and 0.77 Å, respectively. We also constructed an 'extrema' set (cite the protocol paper) of 61,687 molecules using the DUDE-Z web server (http://tldr.docking.org) to ensure that molecules with extreme physical properties were not enriched. The docking setup enriched close to 90% mono-cations among the top1000 ranking molecules. In order to check if the limited amounts of knowns and property-matched decoys over-trained the docking parameters, the enrichment test was run using 574 additional Four-hundred and ninety million cations from ZINC15 (http://zinc20.docking.org), characterized by similar physical properties as σ 1/2 known ligands (for instance, with calculated octanol-water partition coefficients (cLogP) <=5 and with 250 Da